Comment on CMS-2026-1256-0002

Summary: Pfizer, Inc. opposes several components of the proposed rule, specifically the repeal of NTAP alternative pathways for certain drugs and devices, the shortening of the NTAP newness period, and the removal of COVID-19 vaccination quality measures. The company argues that these changes would create unnecessary regulatory burdens, undermine data integrity for rate-setting, and reduce protections for high-risk patient populations.